FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze drug delivery technology

Roche has received the Food and Drug Administration’s clearance for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with Halozyme's Enhanze drug delivery technology. 

The medication is indicated for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis as a twice-a-year, approximately 10-minute subcutaneous injection to be administered by a healthcare practitioner.

Halozyme noted that Ocrevus Zunovo has the potential to expand treatment options to centers without IV infrastructure or with IV constraints

[Read more: Walgreens, Cariloop support patients with Multiple Sclerosis]

"We are pleased that the subcutaneous formulation of Ocrevus, Ocrevus Zunovo, which contains our Enhanze drug delivery technology, is now approved in the U.S. for patients with these two forms of multiple sclerosis," said Helen Torley, president and CEO of Halozyme. "Ocevus Zunovo offers greater treatment flexibility and optionality for patients with multiple sclerosis and their healthcare providers."